← SynDRA
VELPATASVIR
SynDRA canonical compound SYN0038213 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | antiviral |
|---|
| Indication | hepatitis C |
|---|
| Disease area | infectious disease |
|---|
All known targets
- HCV NS3/4A
- HCV NS5A
- HCV NS5B
- NS5A
Mechanisms of action (all sources)
Drug classes
- Anti-Infective Agents
- Antiviral Agents
- P-Glycoprotein Inhibitors
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Organic Anion Transporting Polypeptide 2B1 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Hepatitis C Virus NS5A Inhibitor
ATC classes
Cross-references
Synonyms
- GS-5816
- GS5816
- Velpatasvir component of epclusa
- Velpatasvir component of vosevi
- GS 5816
- KCU0C7RS7Z
- CHEBI:133009
- EPCLUSA COMPONENT VELPATASVIR
- velpatasvirum
- RefChem:901782
- DTXCID401513466
- MFCD28411371
- Velpatasvir R Isomer (Imidazole)
- UNII-KCU0C7RS7Z
- Velpatasvir [USAN:INN]
- C49H54N8O8
- Velpatasvir [INN]
- Velpatasvir (Standard)
- Velpatasvir(GS5816)
- VELPATASVIR [MI]
- VELPATASVIR [JAN]
- Velpatasvir(GS5816)?
- Velpatasvir; GS-5816
- VELPATASVIR [USAN]
- VELPATASVIR [WHO-DD]
- Velpatasvir (JAN/USAN/INN)
- orb1304313
- SCHEMBL8756902
- SCHEMBL19236068
- SCHEMBL29361950
- SCHEMBL29678287
- SCHEMBL30743167
- SCHEMBL31554853
- GTPL11269
- VELPATASVIR [ORANGE BOOK]
- FHCUMDQMBHQXKK-CDIODLITSA-N
- GLXC-90501
- Epclusa (sofosbuvir + velpatasvir)
Reported adverse events
- Bradycardia
- Angioedema
- Depression
- Rash
- Lipase
- Irritability
- Vomiting
- Asthenia
- Depressed mood
- Fatigue
- Headache
- Insomnia
Look up VELPATASVIR in the interactive SynDRA portal →